Blood cancer, Cancer, Leukemia
SNDXSyndax PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Revumenib w/ 7+3 cytarabine + daunorubicin in Blood cancer, Cancer, Leukemia. The expected timing is based on the latest available company guidance and may change.
Initiated trial in Q2 '24. 1/13/25- Report data in H2 2025. 11/03/25:- Preliminary data from two intensive chemotherapy Ph1 7+3 revumenib trials to be presented at ASH 2025. 12/08/25:- ASH 2025 Ph1 SNDX-5613-0708 intensive chemo trial showed 96% ORR, 92% CRc, favorable safety. 02/26/26:- ASH 2025 preliminary Ph1 revumenib+7+3 chemotherapy data reiterated; intensive chemotherapy trials remain ongoing. 04/30/26:- Phase 1 intensive 7+3 frontline data expected in Q2 2026. 05/12/26:- Updated Phase 1 SNDX-5613-0708 intensive chemo results will be presented at EHA 2026 June 12. 06/11/26:- EHA 2026 SNDX-5613-0708 Ph1 showed 97% CRc and 86% MRD negativity. 08/04/26:- Intensive chemotherapy Ph1 frontline data expected at H2 2026 medical meetings.
Verification
Confirm timing and program details against the company announcement or filing.